Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma.

Kevin Campbell,Andrew Posner,Nan Chen,Kerri Cavanaugh,Ketki Bhushan,Katherine A Janeway,David S Shulman,Suzanne George,Kelly Klega,Brian Crompton,Wendy B London,Steven G DuBois

Pediatric blood & cancer（2023）

引用 0|浏览10

暂无评分

摘要

The recommended phase 2 doses and schedules for this combination are topotecan 0.75 mg/m IV days 1-5, cyclophosphamide 250 mg/m IV days 1-5, and cabozantinib 25 mg/m days 8-21. Non-concomitant administration of cabozantinib with cytotoxic therapy in this population has acceptable toxicity, while allowing for potential disease control.

查看译文

关键词

cabozantinib, cyclophosphamide, phase 1, relapsed Ewing sarcoma, relapsed osteosarcoma, topotecan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要